Cambridge headquartered AstraZeneca saw its UK share price rocket 328p to 11,118 and its market cap soar to £173.49 billion after a stunning set of results for the first half and second quarter of ...

Reports Q2 revenue $14.46B, consensus $14.56B. “Our strong momentum in revenue growth continued through the first half of the year and the ...

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...

Pharmaceutical giant AstraZeneca has reported increased revenue across all its major geographic regions and increased interim profits as the listed business maintained its growth ...

Revenue from oncology products made up 43 per cent of Astrazeneca's revenue in the first half of 2025, up 15 per cent year on ...

AstraZeneca PLC (NASDAQ:AZN) is one of the Stocks With Huge Catalysts on the Horizon. On July 24, AstraZeneca PLC (NASDAQ:AZN ...

(Sharecast News) - London stocks ended lower on Monday, erasing earlier gains as investors reassessed the weekend's trade agreement between the United States and the European Union. The FTSE 100 index ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

Detailed price information for Astrazeneca Plc Ord (AZNCF) from The Globe and Mail including charting and trades.

Astrazeneca plc seems on the way to expanding its presence in myasthenia gravis (MG) with positive “high-level” results from ...